Pharmacy Pearls: Lipid Management – Vascepa and Statin Intolerance

February 5th, 2020 | Pharmacy Pearls•Cardiology

This edition of Pharmacy Pearls critically reviews the data of the REDUCE-IT trial for Vascepa, which resulted in its new FDA-labeled indication for cardiovascular risk reduction with mild hypertriglyceridemia. We have also included an algorithm for how to address statin-associated muscle symptoms (SAMS).

As always, we welcome any questions or feedback you may have.

Just email the Pharmacy Team.

PP Feb 2020 Vascepa and Statin Intolerance

135 Corporate Woods, Suite 320
Rochester, New York 14623-1466

Phone: (585) 758-7823
Fax: (585) 424-1268

Website by:

This is not an offer to purchase or a solicitation of an offer to purchase any securities or interest in Accountable Health Partners, LLC (AHP). An offer will only be made by means of a confidential private placement memorandum and subscription agreement.

ABI Value	Interpretation	Recommendation
Greater than 1.4	Calcification/vessel hardening	Refer to vascular specialist
1.0 - 1.4	Normal	None
0.9 - 1.0	Acceptable	None
0.8 - 0.9	Some arterial disease	Treat risk factor
0.5 - 0.8	Moderate arterial disease	Refer to vascular specialist
Less than 0.5	Severe arterial disease	Refer to vascular specialist

Pharmacy Pearls: Lipid Management – Vascepa and Statin Intolerance

Pharmacy Pearls: Lipid Management – Vascepa and Statin Intolerance

GENERAL COVID-19 INFORMATION